Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Protocols / Assay of TMPRSS2:ERG and PCA in Canary PASS

Assay of TMPRSS2:ERG and PCA in Canary PASS


No involved investigator sites defined.

Urinary PCA3 and TMPRSS2:ERG
Prostate and Urologic Cancers Research Group

The identification of biomarkers that, at the time of diagnosis, associate with the presence of, or progression to, aggressive prostate cancer will transform the clinical management of this malignancy. If patients and their physicians have reliable and valid tools for estimating the risk of disease-specific morbidity, then more patients might opt for and adhere to active surveillance regimens, and consequently reduce overtreatment and the attendant substantial costs and harms. Also, a marker or marker panel with high accuracy for progression on active surveillance will identify those men who could be placed on less intensive surveillance protocols with fewer repeated prostate biopsies, reducing the risks and costs of invasive procedures. The study presented here is a step toward validating such biomarkers.

1.   Assess the frequency of TMPRSS2:ERG gene-fusion in whole urines of an active surveillance population. 2.   Evaluate urinary TMPRSS2:ERG and PCA3 levels and assess if there is a correlation with progression. 3.   Evaluate longitudinal changes in urinary TMPRSS2:ERG and PCA3 levels and assess if there is a correlation with progression.
Gen-Probes TMA assay

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.

2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 12/02/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh ( no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.